Bristol Myers, Nvidia SuperPOD 구매 — 과연 신약 개발 속도를 높일 수 있을까?
Bristol Myers Squibb가 신약 개발을 위해 Nvidia DGX SuperPOD를 구매했습니다. 이 움직임은 제약 R&D 파이프라인에 수직 AI를 통합하려는 경쟁을 예고합니다.
bristol myers squibb is deploying an nvidia dgx superpod powered by the vera rubin architecture. the system aims to streamline artificial intelligence across its drug discovery and development workflows. it marks the first deployment of this architecture in the life sciences sector. this signals a shift from experimental ai tools to essential infrastructure for competitive biotech research.